aglatimagene besadenovec
AssetAlso AdV-tk, Canatak, Gliatak, Oncatak
Adenoviral vector expressing HSV-tk combined with valacyclovir to induce tumor cell death and immune reactivation.
- Stage
- Phase 2
- Modality
- Gene therapy
- Target
- Apoptosis
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Non-small cell lung cancer
Phase 2, globenewswire.com, 1 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.